Arrowhead Research | ARWR - Ebitda


Arrowhead Research reported $-107.35M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -107.35M 164.52M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Moderna USD -1.26B 468M Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
TG Therapeutics USD 28.11M 23.58M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xencor USD -34.63M 86.74M Jun/2026